Celyad Oncology S.A.
Celyad Oncology S.A. (CYAD) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cyad · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Celyad Oncology S.A. (CYAD) measures how much investors pay for each dollar of the company's trailing earnings. CYAD's current PE ratio of 13.38x is calculated by dividing its stock price of $0.47 by its TTM earnings per share of $0.02.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2010 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Celyad Oncology S.A.You CYAD | $14M | 13.38x | — | $0.02 |
 AlphaTON Capital Corp. ATON | $1M | N/A | — | -$5.72 |
 Axcella Health Inc. AXLA | $13M | N/A | — | -$1.27 |
 Gelesis Holdings, Inc. GLS | $12M | N/A | — | -$0.79 |
 TuHURA Biosciences, Inc. HURA | $133M | N/A | — | -$0.63 |
 Imunon, Inc. IMNN | $5M | N/A | — | -$6.83 |
 Kineta, Inc. KA | $7M | N/A | — | -$1.42 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $-0.14 | — | |
2023-12-31 FY2023 | — | $-0.33 | — | |
2022-12-31 FY2022 | — | $-1.81 | — | |
2021-12-31 FY2021 | — | $-1.70 | — | |
2020-12-31 FY2020 | — | $-1.26 | — | |
2019-12-31 FY2019 | — | $-2.29 | — | |
2018-12-31 FY2018 | — | $-3.36 | — | |
2017-12-31 FY2017 | — | $-5.86 | — | |
2016-12-31 FY2016 | — | $-2.53 | — | |
2015-12-31 FY2015 | — | $-3.43 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Celyad Oncology S.A. (CYAD) measures how much investors pay for each dollar of the company's trailing earnings. CYAD's current PE ratio of 13.38x is calculated by dividing its stock price of $0.47 by its TTM earnings per share of $0.02.
Frequently asked questions
CYAD pe ratio · 6 questionsCYAD's current PE ratio is 13.38x as of 2026-06-09, based on a stock price of $0.47 and TTM EPS of $0.02. Data sourced from Financial Modeling Prep via CYAD's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Celyad Oncology S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09